热门资讯> 正文

MacroGenics从赛诺菲获得2450万美元的Tzield批准

2026-06-23 05:13

赛诺菲-安万特(SNY) 0
Sanofi(GCVRZ) 0

Sanofi (SNY) is providing MacroGenics (MGNX) a $24.5M milestone payment following the recently approved additional indication of Tzield (teplizumab) to delay the decline in endogenous insulin production in children ages 8-17 years recently diagnosed with stage 3 type 1 diabetes.
MacroGenics can still receive up to an additional $305M in milestones as well as a potential single-digit royalty on global sales above a certain annual amount.

More on MacroGenics

MacroGenics: Oncology Opportunities In Play, But Investing Feels Like A Gamble
MacroGenics GAAP EPS of -$0.58 misses by $0.03, revenue of $20.78M beats by $5.54M
MacroGenics to sell manufacturing operations to Bora for $122.5M
Seeking Alpha’s Quant Rating on MacroGenics
Historical earnings data for MacroGenics

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。